BrainStorm Cell Therapeutics Inc. (BCLI) income statement

BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 0/30

$0.77−0.01 (-1.17%)

Close on Oct 19, 2026Market cap $8.50MP/E –Yield –

BrainStorm Cell Therapeutics Inc. income statement

Annual Quarterly TTM

Periods

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 CY2025 2025-12-31	FY 2024 CY2024 2024-12-31	FY 2023 CY2023 2023-12-31	FY 2022 CY2022 2022-12-31	FY 2021 CY2021 2021-12-31	FY 2020 CY2020 2020-12-31	FY 2019 CY2019 2019-12-31	FY 2018 CY2018 2018-12-31	FY 2017 CY2017 2017-12-31	FY 2016 CY2016 2016-12-31	FY 2015 CY2015 2015-12-31	FY 2014 CY2014 2014-12-31	FY 2013 CY2013 2013-12-31	FY 2012 CY2012 2012-12-31	FY 2011 CY2011 2011-12-31	FY 2010 CY2010 2010-12-31	FY 2009 CY2009 2009-12-31	FY 2008 CY2008 2008-12-31	FY 2006 CY2005 2006-03-31	FY 2005 CY2004 2005-03-31
Research & Development	4.18	4.65	11	14	15	22	17	8.29	0.98	2.25	4.95	4.77	2.92	1.77	1.69	1.05	–	–	–	–
General & Administrative	5.78	7.04	11	11	9.30	9.36	5.80	5.77	4.02	2.83	3.59	2.65	2.13	1.75	2.21	1.54	–	–	–	–
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	7.42	5.04	3.52	3.89	2.59	–	–	–	–
Operating Income	-9.95	-12	-21	-25	-25	-32	-23	-14	-5.00	-5.08	-8.54	-7.42	-4.90	-3.43	-3.91	2.40	–	–	–	–
Interest Expense	–	–	–	–	–	–	–	–	–	–	–	–	–	-0.09	0.15	0.19	–	–	–	–
Pretax Income	-10	-12	-17	-24	-24	-32	-23	-14	-4.95	-4.98	-8.49	-9.25	-4.90	-3.43	-3.92	–	–	–	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	0	0	0	0	0	0.01	0.01	-0.02	–	–	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	-4.90	-3.43	-3.92	2.42	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	–	–	–	–
Net Income incl. Noncontrolling Interests	-10	-12	-17	-24	-24	-32	-23	-14	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-10	-12	-17	-24	-24	-32	-23	-14	-4.95	-4.98	-8.49	-9.25	-4.90	-3.43	-3.92	-2.42	-1.78	-3.47	-3.32	-19
EPS (Basic)(per share)	-1.11	-2.31	-6.00	-9.90	-10.20	-16.05	-15.90	-10.50	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Diluted)(per share)	-1.11	-2.31	-6.00	-9.90	-10.20	-16.05	-15.90	-10.50	–	–	–	–	–	–	–	–	–	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	9.27	5.02	2.87	2.43	2.41	1.99	1.46	1.33	1.25	1.24	1.23	0.91	0.72	0.61	0.53	–	–	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	9.27	5.02	2.87	2.43	2.41	1.99	1.46	1.33	1.25	1.24	1.23	0.91	0.72	0.61	0.53	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: 116.1%

Financial strength

Current ratio: 0.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

See a number that looks wrong?